PLIANT THERAPEUTICS, INC. Logo

PLIANT THERAPEUTICS, INC.

Developing novel integrin-based therapies for fibrosis and related diseases.

PLRX | US

Overview

Corporate Details

ISIN(s):
US7291391057
LEI:
Country:
United States of America
Address:
331 OYSTER POINT BOULEVARD, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The company leverages its proprietary discovery platform to create tissue-specific, integrin-based therapies. Its scientific approach centers on understanding and modulating the molecular drivers of fibrotic diseases, particularly TGF-β1 signaling, to develop potentially safer and more effective treatments. Pliant's development pipeline includes programs targeting a range of conditions, such as idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLIANT THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLIANT THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PLIANT THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America GILD
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary GWPH
Gossamer Bio, Inc. Logo
Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.
United States of America GOSS
Grace Therapeutics, Inc. Logo
Develops improved drugs for rare neurological diseases using novel drug delivery technologies.
United States of America GRCE

Talk to a Data Expert

Have a question? We'll get back to you promptly.